US Patent 8,298,554: Scope, Claims, Expiration, Orange Book Status and Vascepa Patent Landscape

US Patent 8,298,554 protects highly purified eicosapentaenoic acid, particularly ethyl eicosapentaenoate, in a stabilized softgel capsule. The patent combines three technical limitations: an EPA-rich fill, defined peroxide-value stability after accelerated storage, and a capsule shell using specified hygroscopic and non-hygroscopic plasticizers.

The patent is directed primarily to the formulation and capsule system used for Vascepa, not to every pharmaceutical use of EPA. Its strongest coverage requires a combination of chemical purity, oxidative stability, and shell-composition parameters. A generic product containing icosapent ethyl could avoid infringement if it falls outside the claimed purity, stability, shell, or dissolution limitations. A product that reproduces the claimed softgel architecture and stability profile faces materially higher risk.

What patents protect the Vascepa icosapent ethyl formulation?

The relevant patent estate includes formulation, therapeutic-use, manufacturing, and later-issued continuation patents. US Patent 8,298,554 is one of the core formulation patents associated with Vascepa.

Patent	Principal subject matter	Strategic relevance
US 8,298,554	EPA-rich composition in a stabilized capsule shell	Protects formulation architecture and oxidative stability
US 8,293,728	Highly purified EPA or ethyl EPA pharmaceutical composition	Protects composition purity and product characteristics
US 8,188,146	Cardiovascular risk-reduction methods using EPA	Method-of-use patent; separately litigated
Later continuation patents	Formulations, dosing, manufacturing, and therapeutic uses	May extend or diversify enforcement positions

The commercial product is Vascepa, containing icosapent ethyl, the ethyl ester of eicosapentaenoic acid. The FDA approved Vascepa in 2012 for severe hypertriglyceridemia and expanded the indication in 2019 to reduce cardiovascular risk in specified patients receiving statin therapy.[1]

US 8,298,554 is important because it claims the product as a physical formulation. A method-of-use patent can be vulnerable to a narrow-label or skinny-label strategy. A formulation patent reaches the product itself and can create direct infringement exposure even when the generic label excludes a patented indication.

What is the technical scope of US Patent 8,298,554?

The independent claims define a softgel product with the following core elements:

At least approximately 95% EPA or an EPA ester by weight of total fatty acids.
Encapsulation in a defined capsule shell.
A baseline peroxide value of no more than 5 meq/kg.
A specified peroxide value after six months under defined temperature and humidity conditions.
A shell containing a film-forming material.
A hygroscopic plasticizer and a non-hygroscopic plasticizer.
A specified ratio between the two plasticizer classes.
Restrictions on succinated or chemically modified gelatin.
In some claims, specific dissolution or pharmacokinetic performance.

The patent therefore does not merely claim “icosapent ethyl in a capsule.” It claims a product meeting a multidimensional formulation profile.

EPA purity requirement

Claims 1 and 20 require at least approximately 95% EPA or EPA ester by weight of total fatty acids. Claims 2 through 6 narrow the composition to ethyl eicosapentaenoate and impose tighter impurity limits.

The dependent claims create progressively narrower purity positions:

Claim	Limitation
2	EPA ester is ethyl eicosapentaenoate
3	Each other individual fatty acid is below about 1%
4	Each other individual fatty acid is below about 0.5%
5	DHA or derivative is below about 0.3%
6	Substantially no DHA or DHA derivative

These limitations distinguish the claimed formulation from ordinary fish-oil products. Conventional fish-oil products commonly contain mixtures of EPA, DHA, other omega-3 fatty acids, and additional lipid components. The patent is directed to a substantially purified EPA product with minimal DHA.

A generic icosapent ethyl product will likely satisfy the EPA identity limitation. The more important factual issues are the exact fatty-acid impurity profile and whether the product contains any individual non-EPA fatty acid above the thresholds in claims 3 and 4.

Oxidative-stability requirement

The patent uses peroxide value as a central product-performance limitation. The independent claim requires:

Baseline peroxide value: no more than 5 meq/kg.
After six months at 25°C and 60% relative humidity: no more than 8 meq/kg.

Other claims impose stricter limits:

Claim	Storage condition	Maximum second peroxide value
1	25°C / 60% RH for six months	8 meq/kg
9	25°C / 60% RH for six months	7 meq/kg
10	25°C / 60% RH for six months	6 meq/kg
11	30°C / 65% RH for six months	12 meq/kg
12	30°C / 65% RH for six months	10 meq/kg
13	30°C / 65% RH for six months	10 meq/kg
14	30°C / 65% RH for six months	6 meq/kg
20	30°C / 65% RH for six months	5 meq/kg
25	25°C / 60% RH for six months	8 meq/kg
27	25°C / 60% RH for six months	5 meq/kg

Peroxide value measures primary lipid oxidation products. For infringement analysis, the relevant testing protocol, sampling plan, batch selection, analytical method, storage packaging, and treatment of assay variability can be material. The claim language makes stability an objective limitation, but the patentee would still need to establish that the accused product meets the specified test conditions.

What capsule shell is protected by US 8,298,554?

The shell limitations are a central part of the patent’s value. The shell must contain:

A film-forming material;
A hygroscopic plasticizer selected from glycerin or glycerol, sorbitol, and alkylene glycols; and
A non-hygroscopic plasticizer selected from maltitol, lactitol, xylitol, hydrogenated starch hydrolysate, and glucose syrup.

The hygroscopic-to-non-hygroscopic plasticizer ratio is approximately 2:1 to 6:1 in claim 1. Claim 16 and related claims narrow the range to approximately 3:1 to 5:1.

The shell also excludes succinated gelatin in claim 1 and chemically modified gelatin in claims 20 and 25. Where the film-forming material is gelatin and the shell includes glycerin or glycerol, the gelatin-to-glycerin ratio must be greater than 5:1. Claims 15, 22, and 31 impose a ratio of at least approximately 5.2:1.

Shell-composition claim map

Claim group	Shell limitation
Claims 1-19	Film former; specified hygroscopic and non-hygroscopic plasticizers; no succinated gelatin
Claims 20-24	Film-forming material free of chemically modified gelatin; EPA ethyl ester; stringent stability
Claims 25-31	Gelatin shell; gelatin-to-total-plasticizer ratio of approximately 1.75:1 to 5:1; plasticizer ratio of approximately 3:1 to 5:1

Claim 25 contains an apparent internal tension. It requires a gelatin-to-total-plasticizer ratio of approximately 1.75:1 to 5:1 and separately requires a gelatin-to-glycerol ratio greater than 5:1 where gelatin and glycerol are present. Claim construction would need to address how those ratios operate together, particularly where the shell contains multiple plasticizers.

How do the dissolution and pharmacokinetic claims affect infringement?

Claims 17, 18, 28, and 29 add dissolution limitations measured by a rotating dialysis cell method. The claimed performance includes:

At least 20% dissolved by 10 minutes;
At least 45% or 50% dissolved by 30 minutes;
At least 80% dissolved by 60 minutes; and
At least 95% dissolved by 100 minutes.

Claims 28 and 29 specify a paddle speed of 100 rpm and pH 1.2. Claim 28 uses “or” in the listed dissolution criteria, while claims 17, 18, and 29 are structured more like cumulative performance requirements. That drafting difference could affect claim construction and enforceability.

Claims 19 and 30 require an EPA Tmax within 5.8 hours after administration to a human subject. These are product-performance limitations tied to pharmacokinetic testing rather than solely to the composition’s ingredients.

A generic manufacturer may challenge whether the rotating dialysis cell method is sufficiently clear, reproducible, and representative of the accused product. The patentee would likely rely on batch testing, regulatory specifications, and comparative dissolution data. A generic may seek to design around these claims through a different shell, excipient system, release profile, or product stability profile.

When does US Patent 8,298,554 lose exclusivity?

The patent has a 20-year US patent term measured principally from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable regulatory patent-term extension.

The relevant public patent records identify an earliest priority date in 2009. On that basis, the ordinary expiration framework points to 2029, subject to the specific term calculation recorded by the USPTO.[2] The patent is not a biologic patent and does not receive the 12-year biologic exclusivity period under the Public Health Service Act.

Exclusivity category	Relevance to US 8,298,554
Patent term	Approximately through 2029 under the priority-date framework
FDA new chemical entity exclusivity	Not applicable to this formulation patent
Orphan-drug exclusivity	Not the principal protection associated with this patent
Pediatric exclusivity	Could extend listed patents if awarded to the product
Patent-term extension	Must be determined from the FDA approval and USPTO records
Regulatory exclusivity for Vascepa	Separate from the patent term and indication-specific

Vascepa received FDA approval in 2012. Its 2019 cardiovascular-risk indication created substantial commercial value for the product, but the 2019 approval did not convert US 8,298,554 into a method-of-use patent. Its protection remains dependent on the formulation claims.

What is the Orange Book status of US 8,298,554?

The Orange Book identifies patents submitted by an NDA holder as covering an approved drug product or an approved method of use. The relevant Orange Book listing must be evaluated by product, NDA, and reporting date because listings can change through patent expiration, delisting, corrections, or FDA administrative action.[3]

For Vascepa, the Orange Book and FDA patent-listing framework are more important than the patent alone because an ANDA applicant must address each listed patent through:

Paragraph I certification;
Paragraph II certification;
Paragraph III certification; or
Paragraph IV certification.

A Paragraph IV certification alleges that the listed patent is invalid, unenforceable, or not infringed. The NDA holder may bring an action within 45 days, triggering a statutory 30-month stay of ANDA approval under the Hatch-Waxman Act.[4]

The Orange Book status of US 8,298,554 should therefore be treated as a live regulatory question tied to the specific Vascepa NDA and the relevant FDA publication date. Patent listing does not establish validity or infringement. It creates an ANDA procedural consequence.

Which companies challenged the Vascepa patent estate?

Amarin brought Hatch-Waxman litigation against generic manufacturers, including Hikma Pharmaceuticals and Dr. Reddy’s Laboratories. The most prominent appellate decision involved US Patent 8,188,146, the cardiovascular-risk-reduction method patent, rather than the full formulation claim set of US 8,298,554.

In Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., the Federal Circuit affirmed invalidity of the asserted method patent based on obviousness.[5] The court’s decision removed a major barrier to generic launch for the cardiovascular indication. It did not establish that every Vascepa formulation patent was invalid.

The resulting risk profile differed by patent:

Patent category	Generic risk
Cardiovascular method claims	Reduced after the Hikma appellate decision
Severe-hypertriglyceridemia use claims	Dependent on claim wording and label conduct
Composition and formulation claims	Product-specific; potentially enforceable despite a skinny label
Manufacturing claims	Dependent on the generic’s process and supply chain

Generic icosapent ethyl products entered the US market after litigation and commercial settlements. Settlement terms can affect launch timing, authorized-generic rights, patent waivers, and the indications or product configurations available to the generic. Public litigation outcomes do not necessarily disclose all commercial settlement provisions.

How strong is the patent estate for US 8,298,554?

The patent has moderate-to-strong formulation coverage when the accused product uses the same type of EPA purity, softgel shell, and plasticizer system. Its principal strength is claim aggregation. A challenger must generally show that at least one required limitation is absent, rather than merely arguing that a conventional EPA product is different in one respect.

Strengths

Claims cover the pharmaceutical composition itself.
Claims reach ethyl eicosapentaenoate, the active ingredient in Vascepa.
The claims combine chemical purity with physical formulation attributes.
Stability limitations can be supported by product-development and regulatory data.
Dependent claims provide multiple peroxide-value and plasticizer-ratio positions.
The claims are relevant to the commercial softgel dosage form.

Weaknesses

Several claims depend on narrow and potentially difficult-to-reproduce test conditions.
Peroxide-value limits may create factual disputes concerning assay methodology and batch variability.
Dissolution claims use a specialized rotating dialysis cell method rather than a universally standard release test.
Claim 25 contains potentially conflicting ratio limitations.
A generic may design around the shell composition while maintaining the same active ingredient.
Prior-art risk is significant because purified omega-3 formulations, antioxidants, gelatin shells, plasticizers, and oxidative-stability measures were known individually.

The patent’s enforceability will turn on the combined disclosure and whether the asserted claim is anticipated or rendered obvious by prior-art EPA formulations. The specification’s examples and the prosecution history are important to determine whether the claimed ratios and stability values were treated as critical by the examiner and applicant.

What formulations are most likely to infringe US 8,298,554?

The highest-risk product profile is a softgel containing at least 95% ethyl eicosapentaenoate, little or no DHA, tocopherol or another antioxidant, and a gelatin shell containing glycerol plus maltitol or another listed non-hygroscopic plasticizer.

A product is particularly exposed if testing shows:

Initial peroxide value of no more than 5 meq/kg;
Peroxide value of no more than 8 meq/kg after six months at 25°C and 60% RH;
Hygroscopic-to-non-hygroscopic plasticizer ratio between 2:1 and 6:1;
Gelatin-to-glycerol ratio above 5:1; and
Dissolution performance matching claims 17, 18, 28, or 29.

Claims 7 and 8 separately cover antioxidant-containing compositions, including tocopherol at approximately 0.1% to 1% by weight. A product can satisfy the antioxidant limitation even if the antioxidant is not necessary to meet the peroxide-value limitation.

How can a generic design around the patent?

Potential design-around paths include:

Using a capsule shell with a plasticizer outside the claimed lists.
Altering the hygroscopic-to-non-hygroscopic plasticizer ratio.
Using a non-gelatin film-forming system that is outside the claim language.
Using chemically modified or succinated gelatin where the relevant claim excludes it.
Allowing the product to fall outside a claimed peroxide-value threshold.
Using an EPA composition with an impurity profile outside the dependent-claim limits.
Developing a dissolution profile that does not satisfy the claimed time points.
Using a different dosage form, such as a tablet, liquid, or non-softgel delivery system.

The design-around must be assessed claim by claim. Avoiding one limitation does not avoid a different independent or continuation claim. A product outside the formulation claims could still face method-of-use, manufacturing, or later-issued patent claims.

How does US 8,298,554 compare with the Vascepa method patent?

US 8,298,554 and US 8,188,146 protect different commercial layers.

Issue	US 8,298,554	US 8,188,146
Claim type	Composition and formulation	Method of treatment
Main subject	EPA-rich softgel with stability and shell limits	Cardiovascular risk reduction using EPA
Infringement theory	Product-by-product analysis	Label, prescribing, and induced-infringement analysis
Skinny-label effectiveness	Limited, because product claims remain relevant	More effective where the patented indication is omitted
Key evidence	Composition assay, shell analysis, stability data	Label, marketing, prescribing, clinical indication
Litigation posture	Technical formulation dispute	Subject to major obviousness decision

The invalidation of a method patent does not eliminate formulation-patent risk. Conversely, a strong formulation patent does not automatically prevent all uses of a non-infringing EPA product.

What generic entry risks exist for icosapent ethyl?

Generic entry risk is substantial because icosapent ethyl is a small-molecule active ingredient with an ANDA pathway. The main barriers are formulation replication, patent certifications, commercial settlements, manufacturing controls, and product quality.

The commercial product has already faced generic competition. That reduces the practical value of any patent that does not block the approved generic formulation or that is no longer enforceable against the launched products.

For an entrant, the key diligence questions are:

Whether US 8,298,554 remains listed for the relevant NDA.
Whether an ANDA applicant filed a Paragraph IV certification.
Whether the product’s shell matches the claimed plasticizer system.
Whether the applicant’s stability data satisfy the peroxide limitations.
Whether the generic label includes any patented use.
Whether the product is manufactured using a process covered by a separate patent.
Whether a settlement permits entry before the ordinary patent expiration date.

What licensing deals affect the Vascepa patent landscape?

Amarin has used licensing and commercialization arrangements in connection with Vascepa outside the United States. These agreements can allocate rights by territory, indication, manufacturing source, or regulatory responsibility. They do not automatically transfer US patent ownership or alter the Orange Book listing.

The commercial significance of a license depends on whether it includes:

Patent sublicensing rights;
Authority to prosecute or enforce patents;
Supply rights for icosapent ethyl;
Rights to launch an authorized generic;
Geographic exclusivity;
Royalty obligations; and
Settlement-related launch rights.

Publicly available records should distinguish assignment of patent ownership from a commercial license. The USPTO assignment database, SEC filings, FDA records, and court dockets are the principal sources for that distinction.[2,6]

Key Takeaways

US 8,298,554 is a formulation patent covering EPA-rich, particularly ethyl-eicosapentaenoate, softgel compositions.
The claims require a combination of EPA purity, low initial peroxide value, long-term oxidative stability, and specified capsule-shell chemistry.
Claims 3 through 6 target low levels of non-EPA fatty acids and DHA.
Claims 15, 16, 22, 24, and 31 impose narrow gelatin and plasticizer ratios.
Claims 17, 18, 28, and 29 add specialized dissolution requirements.
Claims 19 and 30 add a human EPA Tmax limitation.
The ordinary patent-term framework points to expiration in 2029, subject to the official USPTO term calculation.
Generic entry is more exposed to formulation claims than to use claims because a skinny label may avoid a method patent but not a product patent.
The most vulnerable design-around points are the shell composition, plasticizer ratio, peroxide-value profile, impurity profile, and dissolution behavior.
The patent should be analyzed with the related Vascepa composition, method-of-use, manufacturing, Orange Book, and litigation records rather than in isolation.

FAQs About US Patent 8,298,554

Does US 8,298,554 claim Vascepa by name?

No. The claims use chemical and performance characteristics, principally EPA purity, ethyl eicosapentaenoate, peroxide values, capsule-shell ingredients, plasticizer ratios, dissolution, and Tmax.

Can a generic icosapent ethyl product avoid US 8,298,554?

Yes, if it lacks at least one required limitation of every asserted claim. The most practical design-around targets are the capsule-shell formulation, plasticizer ratio, stability profile, and impurity profile.

Is US 8,298,554 a method-of-use patent?

No. It is principally a composition and formulation patent. Its claims cover the pharmaceutical product and, in dependent claims, product-performance characteristics.

Does the Hikma decision invalidate US 8,298,554?

No. The major Hikma appellate decision addressed US 8,188,146, a cardiovascular-risk-reduction method patent. It did not automatically invalidate US 8,298,554.

Why are peroxide values important in the patent claims?

Peroxide values quantify primary oxidation products in the EPA formulation. The claims use defined peroxide-value limits as objective evidence that the composition remains chemically stable during storage.

References

U.S. Food and Drug Administration. (2012). FDA approves use of Vascepa to treat very high triglyceride levels. FDA.
United States Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment Search: U.S. Patent No. 8,298,554. USPTO.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 923 F.3d 1027 (Fed. Cir. 2019).
Amarin Corporation plc. (2020-2024). Annual reports and SEC filings. U.S. Securities and Exchange Commission.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010241571	⤷ Start Trial
Brazil	PI1011876	⤷ Start Trial
Canada	2759284	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,298,554

Which drugs does patent 8,298,554 protect, and when does it expire?

Summary for Patent: 8,298,554